

*In vivo* imaging to de-risk your medical innovations






Ali AÏT-IKHLEF - Chargé des partenariats

Commissariat à l'énergie atomique et aux énergies alternatives - www.cea.fr



Four close, complementary and multidisciplinary centers





- Unique in vivo imaging platforms and expertise: MRI, PET, ultrasound, optical and hybrid imaging

- From POC in animal to drug development in patients



## Unrivaled in vivo imaging expertise & platforms for translational research



Radiotracers	РЕТ	Multimodal Imaging	Radiopharmaceuticals	PET	Multimodal Imaging	
<ul> <li>✓ 3 cyclotrons: <sup>11</sup>C , <sup>18</sup>F, <sup>15</sup>O, <sup>68</sup>Ga</li> <li>✓ Access to <sup>89</sup>Zr, <sup>177</sup>Lu and <sup>64</sup>Cu</li> <li>✓ Labelling of small and large molecule</li> </ul>	Dedicated animal PET Scanners (brain & whole body)	PET-CT / PET-MRI / PET-US / SPECT-CT / MRI-US			PET-CT / PET-MRI / SPECT-CT	
molecule						
	Preclinical research			<b>Clinical Phases</b>		
	C					
Two-photon microscopy	MRI	Ultrasound	MRI		Ultrasound	
Multiple labeling	3T / 7T / 11.7T /17.2T	Imaging & Therapeutical	3T / 7T / 11,7	ΥT		
	✓ Rodents & N	HP				


✓ BSL1 to 3 environment



# Some illustrative cutting-edge applications









Characterization of 3 ligands derived from the anti-PD-L1 lgG1 using <sup>89</sup>Zr in a xenograft model

### Mn2+ Enhanced MRI




Drug effects on functional neuroimaging in mouse

### PET-CT






Infection effect of Sars-Cov-2 in NHP -(18F)FDG



PET

Gene therapy efficacy on a NHP model of Parkinson's disease - (<sup>18</sup>F) G- FMT

#### PET/MRI



Biodistribution of marketed drug PET Microdosing - ("C)Glyburide

- ightarrow Efficacy using specific biomarkers
- ightarrow Biodistribution and PK-PD
  - > Optimization of dose, route and schedule of administration
  - Prediction of efficacy and/or toxicity of a drug
  - Receptor occupancy
- ightarrow Translational development



## A rich research environment



-----



#### **BSL 1-2-3 ENVIRONMENTS**

FER	Animal models	Genomics	Viral vector production	Anatomopathology	Comming	MEC	Anatomopathology
FULL SET OF OF	General and stereotactic surgery	Proteomics	Biotherapy	Immunohistochemistry	Genomics	MEG	Immunohistochemistry
	Cognitive and motor behavior Flow & Mass spectrometry	Metabolics	Aptamer	Optical imaging	BioBanking	EEG	Optical imaging
RESEARCH EXPERTISE	Cell sorting	Biochemistry	BioBanking	Ex vivo imaging	Proteomics	Machine learning & IA	Ex vivo imaging
	Neurodegenerative diseases		Oncology		Chronic mental illnesses in adult		Research protocol management
	Ophthalmology		Infectious diseases		Neurodegenerative diseases		Brain development pathology
					Brain tumors		Normal aging







**Co-development projects** 

Strategic partnerships

SERVICES

Routine or custom-made services

TRAINING

Collaboration with INSTN

### A project management process

- ✤ A dedicated manager
- Instrument maintenance and calibration
- Data security, confidentiality and storage
- Project traceability
- Formalized protocols
- Compliance with ethical and regulatory aspects
- Staff competence and empowerment



### World-renowned key players with long-standing collaborations with industry
















# Advantages of imaging in drug & biomarker development pipeline



• Main advantages: Quantitative - Non-invasive - Longitudinal - Biomarkers & Drugs - 3R approach



- Pre-clinical
  - Validation of preclinical models
  - Proof-of-concept studies
  - Dose/response relationships
  - Efficacy
  - PK / PD
  - Longitudinal biodistribution
  - Qualification for use in the early clinical trials


- Early clinical trials
  - Target / Side effect
  - Dose selection
  - Stratify study populations
  - So / No Go

- Phase III / registration
  - Stratify populations
  - Predictive response
- Clinical practice
  - Companion diagnostics
  - Stratify populations
  - Predictive response



# A dedicated organization - ISO 9001:2015 certification





#### PROCESSUS DE GESTION DES RESSOURCES









### A one-stop shop to platforms and expertise for drug & biomarker development From POC in animal to drug development in patients

